AI Article Synopsis
- * Researchers analyzed tumor samples from 71 patients and found that high levels of hENT1 expression were linked to better progression-free survival (PFS) and overall survival (OS) in those receiving gemcitabine.
- * The results indicate that higher hENT1 expression could serve as a predictive marker for treatment outcomes in advanced leiomyosarcoma and angiosarcoma patients undergoing gemcitabine therapy.
Article Abstract
Background: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes.
Methods: We retrospectively identified 71 patients affected by advanced angiosarcoma (26) or leiomyosarcoma (45) treated within five Italian referral centres for sarcoma; among them, 49 patients (15 angiosarcoma, 34 leiomyosarcoma) were treated with gemcitabine. All tumour samples were analysed for hENT1 expression by real-time PCR. Median 2 value was used as the cutoff to dichotomise patients into 'high' expression and 'low' expression groups. Kaplan-Meier analysis was performed to estimate progression-free survival (PFS) and overall survival (OS).
Results: We found a significant association between high hENT1 expression levels and favourable outcome in terms of PFS and OS compared to cases with low hENT1 expression in leiomyosarcoma treated with gemcitabine (PFS: 6.8 vs 3.2 months, P=0.004; OS: 14.9 vs 8.5 months, P=0.007). In addition, hENT1 overexpression correlated with a significant improvement in PFS (9.3 vs 4.5 months; P=0.02) and OS (20.6 vs 10.8 months; P=0.001) in angiosarcoma patients treated with gemcitabine.
Conclusions: Our study suggests that higher hENT1 expression are associated to gemcitabine efficacy both in patients with advanced leiomyosarcoma and angiosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537497 | PMC |
| http://dx.doi.org/10.1038/bjc.2017.187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report.
Oncol Lett
August 2024
Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate, over 70%, and is typically treated with gemcitabine (GEM) chemotherapy, though outcomes are often poor.
- A case study of a 63-year-old woman shows she achieved clinical complete remission for over 7 years after receiving GEM monotherapy, even after developing liver metastases post-surgery.
- Analysis of hENT1 protein levels in tumor tissues suggests that assessing hENT1 expression could help predict the efficacy of GEM treatment in PDAC patients.
Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer.
Cancer Manag Res
June 2024
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
Article Synopsis
- The article investigates how the levels of hENT1 affect survival rates in pancreatic cancer (PC) patients treated with the drug Gemcitabine.
- By analyzing 375 surgical tissue samples, researchers found that low hENT1 expression correlated with poorer disease-free survival (DFS) and overall survival (OS) outcomes.
- The study concludes that higher hENT1 expression is associated with better survival for patients receiving Gemcitabine, suggesting it could serve as a predictor for treatment efficacy.
IKZF1 deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1 loss on sensitivity to drugs used in contemporary treatment protocols has remained underexplored. Here we show in experimental models and in patients that loss of IKZF1 promotes resistance to cytarabine (AraC), a key component of both upfront and relapsed treatment protocols.
View Article and Find Full Text PDFLarge-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.
Health Data Sci
January 2024
Department of Bioengineering, Imperial College London, London, UK.
Gemcitabine is a first-line chemotherapy for pancreatic adenocarcinoma (PAAD), but many PAAD patients do not respond to gemcitabine-containing treatments. Being able to predict such nonresponders would hence permit the undelayed administration of more promising treatments while sparing gemcitabine life-threatening side effects for those patients. Unfortunately, the few predictors of PAAD patient response to this drug are weak, none of them exploiting yet the power of machine learning (ML).
View Article and Find Full Text PDFThe prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
Pancreatology
March 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. Electronic address:
Background: FOLFIRINOX and gemcitabine-nabpaclitaxel (GnP) are standard first-line treatment regimens for advanced pancreatic ductal adenocarcinoma (PDAC). However, currently, there is a lack of predictive biomarkers to aid in the treatment selection. We aimed to explore the prognostic and predictive value of class III β-Tubulin (TUBB3) and human equilibrative nucleoside transporter 1 (hENT1) expression, which have previously been shown to be associated with taxane and gemcitabine resistance in advanced PDAC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!